impact of raltegravir on immune reconstitution and thymopoiesis in hiv-1 infected patients with...
TRANSCRIPT
![Page 1: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/1.jpg)
Impact of Raltegravir on Immune Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in Reconstitution and Thymopoiesis in
HIV-1 Infected Patients with HIV-1 Infected Patients with Undetectable ViremiaUndetectable Viremia
Carolina Garrido, N Rallón, N Zahonero, M López, V Soriano, C de Mendoza, and JM Benito
Hospital Carlos III, Madrid
![Page 2: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/2.jpg)
HIV infection and CD4 recoveryHIV infection and CD4 recovery
HIV-infection CD4+T-cellsImmune deficiency
Opportunistic infections
HAART HIV Viral Load CD4+T-cells
Raltegravir First-in-class integrase inhibitor Has proven potent antiviral activity but also showed good immunologic recovery
Background
![Page 3: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/3.jpg)
Raltegravir immunologic outcomes Raltegravir immunologic outcomes Background
THPE0132
700
600
500
400
300
CD
4 co
un
t (c
ell/
mm
3)
ATV DRV RALn
baseline
+ 6 months
Δ CD4
p
CD4+T cells (cell/mm3)
52
524 [344,703]
444 [354,606]
-22 [-127,55]
0.173
25
231 [157-493]
291 [176,492]
28 [-36,80]
0.104
86555 [429-776]630 [472,812]40 [-31,136]
0.012
Switching experiences in HCIII:
- ATV
- DRV
- RAL
Switch one drug for another in a context
of undetectable viremia
![Page 4: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/4.jpg)
Immunologic recovery Immunologic recovery Background
The CD4+T-cell recovery after HAART
can be due to:
Recent thymic emigrants (RTEs)
The expansion of peripheral T cells
Thymus Supply of new lymphocytes to the periphery. Impaired during HIV-infection
Kohler and Thiel, Blood, 2009
![Page 5: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/5.jpg)
Thymic functionThymic function
Thymic function T-cell receptor excision circles (TRECs) Stable DNA episomes
formed during T-cell receptor gene rearrangement within the thymus↑ % cells TREC+ = RTEs
↓ % cells TREC+ = cells after several divisionsTRECs are lost upon cell division
Background
CD31
Surface marker
Present in TREC-rich T-cells
Indicator of recent thymic emigrants
![Page 6: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/6.jpg)
ObjectiveObjective
The aim of the study was
to characterize the immunologic recovery of
HIV-infected patients under suppressed viremia
after switching to a RAL containig regimen
![Page 7: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/7.jpg)
Patients and samplesPatients and samples
Viral load < 50 RNA cop/mL
Baseline +6 months
Switch to a RAL-containig regimenMantain the same regimen
Control group Raltegravir group
For each patient, two blood samples were collected:
one at baseline
one 6 months later
PBMCs were obtained from peripheral blood by density gradient centrifugation
Cells were criopreserved until use
Methods
![Page 8: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/8.jpg)
Immunologic characterizationImmunologic characterization
CD4+T-Lymphocyte
effector naive
effector memory
central memory
- CD4-PC7
- CD45RA-ECD
- CD27-PE
- CD38-PC5
- CD31-FITC
PBMCs were stained with fluorescent-conjugated monoclonal antibodies specific for cell surface markers:
Expression of these surface markers was analyzed by flow cytometry using a 5-color-flow-cytometer FC500 (Coulter, Miami, FL)
Activation marker
Recent thymic emigrants (RTE) marker
Maturation markers
Methods
![Page 9: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/9.jpg)
Study populationStudy population
Baseline characteristics of the study population did not differ among groups
Control group: 84% PI (67% ATV, 17% LPV); 11% NNRTIs; 5% NRTIs
RAL group: 53% PI; 47% 2NRTIs
Results
![Page 10: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/10.jpg)
CD4CD4++T-cell countT-cell count
After the 6-month period, only the group who switched to RAL experienced a significant change in CD4 count
Control
800
600
400
200
0
Raltegravir
CD
4+T
-ce
ll (
ce
ll/m
m3 )
*
Results
![Page 11: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/11.jpg)
CD4CD4++T-cell maturationT-cell maturation
Effector
Naive
Effector memory
Central memory
Effector
Naive
Effector memory
Central memory
0.421
0.014
0.005
0.421
0.117
0.199
0.723
0.133
*
*
Wilcoxon Signed Ranks Testp
After the 6-months period, significant changes in the population subsets distribution only occurred in the RAL group, where the subset of naive cells increased its proportion
+6 monthsBaseline
Co
ntr
ol
Ral
teg
ravi
r
Results
![Page 12: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/12.jpg)
CD31 expressionCD31 expression
CD31 expression did not vary significantly in any of the study groups neither in the whole population or in particular cellular subsets
Results
Baseline
+ 6 months
p=0.811
p=0.306p=0.191
p=0.420
p=0.679p=0.277
p=0.306
p=0.872
p=0.314
p=0.117
![Page 13: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/13.jpg)
CD38 expressionCD38 expression
In the control group there was a slightly significant decrease in the CD38 expression level of both naive and effector subsets
In the RAL group, we observed a significant decrease in the effector population but a significant increase in the level of CD38 expression of naive cells
Results
* ** *
p=0.036
+ 6 months
Baseline
![Page 14: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/14.jpg)
Association between CD38 and CD31Association between CD38 and CD31Results
100806040200
% naïve cells expressing CD31
100
80
60
40
20
0
% n
aïv
e c
ells
exp
ress
ing
CD
38
R Sq Linear = 0,51
Control-RAL + 6 months
Pearson correlation sig (2-tailed) < 0.001
100806040200
100
80
60
40
20
0
R Sq Linear = 0,262
% naïve cells expressing CD31
% n
aïv
e c
ells
exp
ress
ing
CD
38
Control-RAL baseline
Pearson correlation sig (2-tailed) = 0.001
![Page 15: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/15.jpg)
ConclusionsConclusions
Switching to a RAL-containing regimen in a context of suppressed viremia induced a significant gain in CD4+T-cell count.
This improvement was mainly due to an increase in the subset of CD4+Naive cells.
The increase in CD4+naive cells could not be clearly associated to recent thymic emigrants, as there was no significant rise in the expression of CD31.
However, the increase of CD38 expression on naive CD4+T-cells and the significant association between CD38 and CD31 markers on this subset of CD4+ cells, suggest that the immune recovery observed in patients switching to RAL may be due, at least in part, to newly produced cells in the thymus.
![Page 16: Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,](https://reader030.vdocuments.mx/reader030/viewer/2022032805/56649ef15503460f94c02141/html5/thumbnails/16.jpg)
AcknowledgmentsAcknowledgmentsInfectious Diseases Department of Hospital Carlos III
(Molecular Biology Lab. + Clinical Section)
Norma Rallón
Mariola López
Jose Miguel Benito
Natalia Zahonero
Carmen de Mendoza
Vicente Soriano